{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:07:41Z","timestamp":1782364061095,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002387","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA16056"],"award-info":[{"award-number":["CA16056"]}],"id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Szefel Foundation"},{"DOI":"10.13039\/100006398","name":"Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leonard S. LuVullo Endowment for Leukemia Research"},{"name":"Nancy C. Cully Endowment for Leukemia Research"},{"name":"Babcock Family Endowment and the Heidi Leukemia Research Fund"},{"name":"Cancer Clinical Investigator Team Leadership Award (CCITLA)","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]}],"content-domain":{"domain":["bloodreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.blre.2014.12.003","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T13:10:50Z","timestamp":1418994650000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["How we will treat chronic myeloid leukemia in 2016"],"prefix":"10.1016","volume":"29","author":[{"given":"Chetasi","family":"Talati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelena P.","family":"Ontiveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Wetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2014.12.003_bb0005","first-page":"35","article-title":"From the Food and Drug Administration","volume":"286","author":"Schwetz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2014.12.003_bb0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0015","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.12.003_bb0020","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2014.12.003_bb0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0050","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Experts in Chronic Myeloid L","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0055","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","article-title":"Chronic Myelogenous Leukemia, Version 1.2014","volume":"11","author":"O'Brien","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2014.12.003_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2011.02.001","article-title":"Interpretation of cytogenetic and molecular results in patients treated for CML","volume":"25","author":"Vigil","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2014.12.003_bb0070","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.12.003_bb0075","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbmt.2013.01.007","article-title":"Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"19","author":"Arpinati","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2014.12.003_bb0085","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0100","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","article-title":"Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0105","first-page":"237","article-title":"Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly-diagnosed patients with chronic myeloid leukemia in chronic phase: Analysis of ENESTND 3-year data","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2014.12.003_bb0110","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3324\/haematol.2013.091272","article-title":"Safety and efficacy of switching to nilotinib 400mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300mg twice daily","volume":"99","author":"Hughes","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2014.12.003_bb0115","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2014.12.003_bb0120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0125","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","article-title":"Educational session: managing chronic myeloid leukemia as a chronic disease","volume":"2011","author":"Hochhaus","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2014.12.003_bb0135","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0140","doi-asserted-by":"crossref","first-page":"e56813","DOI":"10.1371\/journal.pone.0056813","article-title":"Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice","volume":"8","author":"Santoleri","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2014.12.003_bb0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clml.2011.10.004","article-title":"Managing chronic myeloid leukemia: a coordinated team care perspective","volume":"12","author":"Holloway","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2014.12.003_bb0150","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.12.003_bb0160","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining Key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2014.12.003_bb0165","first-page":"243","article-title":"Resistant mutations in CML and Ph(+)ALL\u2014role of ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.blre.2014.12.003_bb0170","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1182\/blood-2010-02-269233","article-title":"Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS","volume":"115","author":"Mahadeo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0175","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2014.12.003_bb0185","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.hoc.2011.09.003","article-title":"Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era","volume":"25","author":"Jain","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2014.12.003_bb0190","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2014.12.003_bb0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.12.003_bb0205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T02:55:34Z","timestamp":1598583334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X14001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0268960X14001015"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2014.12.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we will treat chronic myeloid leukemia in 2016","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}